Skip to content
Ejaculation.org

Randomised controlled trial · 2006

Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire

Arafa M, Shamloul R (2006). Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire. International Journal of Impotence Research. doi:10.1038/sj.ijir.3901469

Key finding
In a single-blind crossover trial of sertraline versus placebo for PE, most men improved on sertraline, but 66 of 100 men followed up (66%) relapsed within 6 months of stopping it.

Summary

This single-blinded, randomised, placebo-controlled crossover study tested sertraline, a selective serotonin reuptake inhibitor (SSRI), in men with premature ejaculation (PE). It enrolled 147 men, randomised into two groups that received sertraline and placebo in turn for four weeks each. Results were measured with the Arabic Index of Premature Ejaculation, a validated questionnaire.

Most men experienced a significant improvement in their questionnaire score while taking sertraline, and the drug was generally well tolerated. Of the 100 men available for follow-up after treatment ended, 66 (66%) had a relapse of PE within six months of stopping sertraline.

Limitations

Only the participants, not the researchers, were blinded, treatment periods were short, and outcomes were measured by questionnaire rather than stopwatch. The abstract reports inconsistent denominators for the response rate, and follow-up was incomplete.

What it means for you

An SSRI can delay ejaculation while you take it, but in this study two out of three men were back where they started within six months of stopping. That is normal for this kind of medicine, and it is why skills that last, such as arousal awareness and pelvic floor control, are worth building alongside or after it.